-
公开(公告)号：US20230241098A1
公开(公告)日：2023-08-03
申请号：US18002666
申请日：2021-06-28
IPC分类号： A61K31/737 , A61P31/16 , A61K9/00
CPC分类号： A61K31/737 , A61P31/16 , A61K9/0043
摘要： Pharmaceutical compositions are described comprising fucoidan for use in a method for the treatment or the prevention, by intranasal administration, of an infection with rhinovirus or respiratory syncytial virus in a human. Particularly, the viral infection is HRV-C15, HRV-A16, or HRV-B14 infection or RSV type A infection. There are also described pharmaceutical compositions comprising fucoidan for use in a method for prevention of rhinovirus spread or respiratory syncytial virus spread in a human population, wherein subjects of the population are tested for infection with HRV-C15, HRV-A16, or HRV-B14 or RSV type A and infected subjects are treated with intranasal administration of the pharmaceutical composition.
-
公开(公告)号：US20230270802A1
公开(公告)日：2023-08-31
申请号：US18002665
申请日：2021-06-28
IPC分类号： A61K36/03 , A61K31/737 , A61K9/08 , A61K9/00 , A61P31/14
CPC分类号： A61K36/03 , A61K9/08 , A61K9/0043 , A61K31/737 , A61P31/14
摘要： Pharmaceutical compositions are described comprising fucoidan for use in a method for the treatment or the prevention, by intranasal administration, of coronavirus infection in a human. Particularly, the viral infection is OC43 or SARS-CoV-1 or SARS-CoV-2 infection. There are also described Pharmaceutical compositions comprising fucoidan for use in a method for prevention coronavirus spread in a human population, wherein subjects of the population are tested for infection with OC43 or SARS-CoV-1 or SARS-CoV-2 and infected subjects are treated with intranasal administration of the Pharmaceutical composition.
-
搜索结果
2 条记录 (耗时 0.011 秒)
